鄰近類別 圖書 [1/1] 會議論文/會議摘要 [119/183] 專利 [0/4] 類別統計 近3年內發表的文件:35(10.48%) 含全文筆數:331(99.10%) 文件下載次數統計 下載大於0次:331(100.00%) 下載大於100次:320(96.68%) 檔案下載總次數:147262(77.63%) 最後更新時間: 2025-04-26 14:42 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Multicenter prospective first-line ... Pan-Asian adapted ESMO clinical pra... Perspectives of the medical oncolog... Cooperative participation of CagA a... Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI...

跳至: (選擇年份) 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-25 / 334. (共14頁) 1 2 3 4 5 6 7 8 9 10 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2025-03	Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study	European Journal of Surgical Oncology. 2025 Mar;51(3):Article number 109544.
2025-02-06	Multicenter prospective first-line helicobacter pylori eradication for localized gastric “Pure” diffuse large B-cell lymphoma	American Journal of Hematology. 2025 Feb 06;Article in Press.
2025-01	Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer[Erratum:ESMO Open. 2024 Aug 06;9(8):Article number 103647.]	ESMO Open. 2025 Jan;10(1):Article number 104074.
2024-11-18	Cooperative participation of CagA and NFATc1 in the pathogenesis of antibiotics-responsive gastric MALT lymphoma	Cancer Cell International. 2024 Nov 18;24:Article number 383.
2024-10	A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study	Oncologist. 2024 Oct 3;29(10):e1396-e1405.
2024-08-20	Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri	Gastric Cancer. 2024 Aug 20;Article in Press.
2024-08-06	Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer	ESMO Open. 2024 Aug 06;9(8):Article number 103647.
2024-08	Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study	Lancet. Gastroenterology and Hepatology. 2024 Aug;9(8):694-704.
2024-07-11	Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study	BMC Cancer. 2024 Jul 11;24:Article number 828.
2024-06-21	Topiramate suppresses peri-infarct spreading depolarization and improves outcomes in a rat model of photothrombotic stroke	iScience. 2024 Jun 21;27(6):Article number 110033.
2024-06-17	Plain language summary of the FOENIX-CCA2 study: Futibatinib for people with advanced bile duct cancer	Future Oncology. 2024 Jun 17;Article in Press.
2024-05	Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer	Pancreatology. 2024 May;24(3):600-607.
2024-03	RNF43 inactivation enhances the B-RAF/MEK signaling and greates a combinatory therapeutic target in cancer cells	Advanced Science. 2024 Mar;11(12):Article number e2304820.
2024-02-20	Chromatin remodeling-related PRDM1 increases stomach cancer proliferation and is counteracted by bromodomain inhibitor	Journal of Personalized Medicine. 2024 Feb 20;14(3):Article number 224.
2024-02-15	Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1/Akt pathway	American Journal of Cancer Research. 2024 Feb 15;14(2):448-466.
2024-02-13	Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan	Journal of Biomedical Science. 2024 Feb 13;31:Article number 21.
2024-02-01	Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression	Liver Cancer. 2024 Feb 01;Article in Press.
2023-11-22	The prognosis performance of a neutrophil- and lymphocyte-associated gene mutation score in a head and neck cancer cohort	Biomedicines. 2023 Nov 22;11(12):Article number 120209.
2023-11	Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer	Future Oncology. 2023 Nov;19(34):2277-2289.
2023-10	The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: A noninterventional, uncontrolled multicenter study	British Journal of Cancer. 2023 Oct;129(6):947-955.
2023-09-01	The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study	International Journal of Surgery. 2023 Sep 1;109(9):2614-2623.
2023-09	Carbohydrate antigen 19-9 response to initial adjuvant chemotherapy predicts survival and failure pattern of resected pancreatic adenocarcinoma but not which patients are suited for additional adjuvant chemoradiation therapy: From a prospective randomized study	International Journal of Radiation Oncology Biology Physics. 2023 Sep 1;117(1):74-86.
2023-08-15	Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination	American Journal of Cancer Research. 2023 Aug 15;13(8):3417-3432.
2023-08	The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study	Cancer Medicine. 2023 Aug;12(16):16906-16917.
2023-07	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462	Annals of Oncology. 2023 Jul;34(7):633.

顯示項目1-25 / 334. (共14頁) 1 2 3 4 5 6 7 8 9 10 > >> 每頁顯示[10|25|50]項目